PIK3CA mutations in advanced ovarian carcinomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The PIK3CA gene encodes a key enzyme in the phosphatidylinositol 3-kinase (PI3K) family, crucial for cell signaling pathways regulating proliferation, survival, and transformation.
• Somatic activating mutations in PIK3CA have been implicated in the development and progression of various human cancers.
• The PI3K/AKT signaling pathway is a critical regulator of cellular functions, and its dysregulation contributes to oncogenesis.

Purpose of the Study:

• To investigate the frequency and spectrum of PIK3CA gene mutations in exon 9 and exon 20 within a cohort of advanced ovarian carcinomas.
• To explore potential correlations between PIK3CA mutations and specific histological subtypes of ovarian cancer, particularly rare types.

Main Methods:

• Direct sequencing was employed to analyze PIK3CA gene mutations in exons 9 and 20.
• A cohort of 109 advanced ovarian carcinoma samples was utilized for the mutation analysis.

Main Results:

• Activating missense mutations in the PIK3CA gene were identified in 4 out of 109 (approximately 3.7%) advanced ovarian carcinomas.
• One additional non-coding variant was detected, resulting in no amino acid change in the PIK3CA protein.
• Notably, two of the four tumors harboring PIK3CA mutations were of the mucinous and clear cell histological subtypes, suggesting a potential enrichment of these mutations in rare ovarian cancer types.

Conclusions:

• PIK3CA gene mutations occur in a subset of advanced ovarian carcinomas.
• The findings suggest that PIK3CA mutations may be more prevalent in rare histological subtypes of ovarian cancer, such as mucinous and clear cell carcinomas.
• Further research into PIK3CA alterations in specific ovarian cancer subtypes could inform targeted therapeutic strategies.